|
|
|||||||||||||||
|
Buscar | Enviar | Ayuda | Servicio de Bibliotecas | Sobre el DDD | Català English Español | |||||||||
| Página principal > Artículos > Artículos publicados > Targeting protein-protein interactions in drug discovery : |
| Fecha: | 2025 |
| Resumen: | Protein-protein interactions (PPIs) form complex cellular networks fundamental to many key biological processes, including signal transduction, cell proliferation and DNA repair. In consequence, their perturbation is often associated with many human diseases. Targeting PPIs offers a promising approach in drug discovery and ongoing advancements in this field hold the potential to provide highly specific therapies for a wide range of complex diseases. Despite the development of PPI modulators is challenging, advances in the genetic, proteomic and computational level have facilitated their discovery and optimization. Focusing on anticancer drugs, in the last years several PPI modulators have entered clinical trials and venetoclax, which targets Bcl-2 family proteins, has been approved for treating different types of leukemia. This review discusses the clinical development status of drugs modulating several PPIs, such as MDM2-4/p53, Hsp90/Hsp90, Hsp90/CDC37, c-Myc/Max, KRAS/SOS1, CCR5/CCL5, CCR2/CCL2 or Smac/XIAP, in cancer drug discovery. |
| Ayudas: | Agencia Estatal de Investigación PID2021-122411OB-I00 Agencia Estatal de Investigación PDC2022-133233-I00 Instituto de Salud Carlos III ICI22/00076 Agència de Gestió d'Ajuts Universitaris i de Recerca 2021/SGR-00835 |
| Nota: | Altres ajuts: acords transformatius de la UAB |
| Derechos: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. |
| Lengua: | Anglès |
| Documento: | Article ; recerca ; Versió publicada |
| Materia: | Protein-protein interaction ; PPI ; Modulators ; Approved ; Clinical trials ; Cancer treatment |
| Publicado en: | Pharmacological research, Vol. 211 (January 2025) , art. 107544, ISSN 1096-1186 |
25 p, 10.0 MB |